Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IBC 2024 | Richter’s transformation: biology & ongoing trials in the field

Carsten Niemann, Erin Parry and Matthew Davids • 25 Mar 2024
IBC 2024
Chronic Lymphocytic Leukemia Leukemia BTK inhibitors

In this discussion, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, Erin Parry, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, and Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discuss updates in the biology of Richter’s transformation (RT), commenting on the impact of novel targeted agents in this space. The experts further highlight exciting clinical trials emerging for patients, including those exploring the use of bispecific antibodies. This session was filmed at IBC 2024, held in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Carsten Niemann

3:20
Explainable machine learning to identify CLL-driven changes on the gut microbiome
Carsten Niemann • 6 Oct 2023
3:27
The implementation of a data-driven CLL-TIM algorithm into an EPIC-based electronic health record
Carsten Niemann • 6 Oct 2023
2:25
Monitoring infection risk in patients with CLL & insights into the PreVent-ACaLL trial
Carsten Niemann • 6 Oct 2023
3:41
The CLL Treatment Infection Model: identifying patients with CLL at high risk of infections
Carsten Niemann • 8 Jun 2023

More from Erin Parry

0:40
Treatment strategies under investigation for Richter's transformation
Erin Parry • 7 Oct 2023
1:36
The genomics of Richter's transformation and evolutionary history of RT from CLL
Erin Parry • 7 Oct 2023
1:17
Diagnosing RT and identifying patients at risk using NGS and molecular cytogenetic analysis
Erin Parry • 7 Oct 2023

More from Matthew Davids

1:53
CLL highlights from ASH 2023: the FLAIR study
Matthew Davids • 9 Dec 2023
2:15
CDK9 inhibition with voruciclib for treating AML and R/R B-cell NHL
Matthew Davids • 9 Dec 2023
1:21
Clinical characteristics and outcomes of the double refractory CLL/SLL patient population
Matthew Davids • 9 Dec 2023
1:47
Future research priorities and unmet needs in patients with CLL
Matthew Davids • 6 Oct 2023

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals